Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682–91. https://doi.org/10.1111/ijcp.12384.

Article  CAS  PubMed  Google Scholar 

Holman R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. J Annu Diabetol Hotel Dieu. 2007;13–20

ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57. https://doi.org/10.2337/dc23-S009.

Article  CAS  PubMed  Google Scholar 

Shaefer CF Jr, Kushner P, Aguilar R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgrad Med. 2015;127(8):818–26. https://doi.org/10.1080/00325481.2015.1090295.

Article  PubMed  Google Scholar 

Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38(6):2821–39. https://doi.org/10.1007/s12325-021-01710-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–30. https://doi.org/10.1007/s40265-019-1057-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho YK, Kim YJ, Jung CH. Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis. J Obes Metab Syndr. 2021;30(4):336–44. https://doi.org/10.7570/jomes21061.

Article  PubMed  PubMed Central  Google Scholar 

Ali AM, Martinez R, Al-Jobori H, et al. Combination therapy with canagliflozin plus liraglutide exerts additive effect on weight loss, but not on HbA1c, in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1234–41. https://doi.org/10.2337/dc18-2460. Ali et al. evaluated the effect of combination GLP-RA and SGTL2 directly on weight loss. Patients were evaluated for 16 weeks of combination therapy with a primary endpoint of mean decrease from baseline in total body weight. There was a significant decrease in weight with those taking combination therapy versus placebo (monotherapy).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Díaz-Trastoy O, Villar-Taibo R, Sifontes-Dubón M, Mozo-Peñalver H, Bernabeu-Morón I, Cabezas-Agrícola JM, et al. GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real world clinical Practice. Clin. Ther. 2020;42(2):e1–e12. https://doi.org/10.1016/j.clinthera.2019.12.012. Díaz et al is a retrospective review on patients taking combination therapy not looking at one specific agent which makes it more generalizable. Those who were on combination therapy did have a significant reduction in HbA1c and had mean weight loss of 3.5 kg and 40% achieved a weight loss of 5% or greater.

Article  CAS  PubMed  Google Scholar 

Li C, Luo J, Jiang M, Wang K. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022;13:838277. https://doi.org/10.3389/fphar.2022.838277.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102.

Article  CAS  PubMed  Google Scholar 

Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published correction appears in Lancet Diabetes Endocrinol. 2020 Mar;8(3):e2]. Lancet Diabetes Endocrinol. 2019;7(10):776–85. https://doi.org/10.1016/S2213-8587(19)30249-9.

Article  CAS  PubMed  Google Scholar 

Trulicity® (dulaglutide) [package insert]. Indianapolis, IN. Eli and Lily and Company; 2017.

Byetta® (exenatide) [package insert]. San Diego, CA. Amylin Pharmaceuticals; 2009.

Bydureon® (exenatide) [package insert]. Wilmington, DE. AstraZeneca Pharmaceuticals LP; 2017

Bydureon BCise® (exenetide ER) [package insert]. Wilmington, DE. AstraZeneca Pharmaceuticals LP; 2017

Victoza® (liraglutide) [package insert] Bagsvaerd, Denmark. Novo Nordisk A/S; 2017

Saxenda® (liraglutide) [package insert] Bagsvaerd, Denmark. Novo Nordisk A/S; 2014

Adylxin® (lixisenatide) [package insert] Bridgewater, NJ. Sanofi. 2021

Ozempic® (semaglutide) [package insert] Bagsvaerd, Denmakr. Novo Nordisk A/S; 2017

Wegovy® (semaglutide) [package insert] Bagsvaerd, Denmakr. Novo Nordisk A/S; 2021

Rybelsus® (semaglutide) [package insert] Bagsvaerd, Denmakr. Novo Nordisk A/S; 2019

Invokana® (canagloflozin) [package insert] Titusville, NJ. Janssen Pharmaceuticals; 2013

Farxiga® (dapagliflozin) [package insert] Princeton, NJ. Bristol-Myers Scquibb Company; 2014

Jardiance® (empagliflozin) [package insert] Indianapolis, IN. Eli Lily and Company; 2016

Steglatro® (ertugliflozin) [package insert] Whitehouse Station, NJ. Merck & Co Inc.; 2017

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989. https://doi.org/10.1056/NEJMoa2032183.

Article  CAS  PubMed  Google Scholar 

Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–13. https://doi.org/10.1001/jama.2021.1831.

Article  CAS  PubMed  Google Scholar 

Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–50. https://doi.org/10.1001/jama.2021.23619.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled rrial (AWARD-11). Diabetes Care. 2021;44(3):765–73. https://doi.org/10.2337/dc20-1473.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–86. https://doi.org/10.1016/S2213-8587(18)30024-X.

Article  CAS  PubMed  Google Scholar 

Cefalu WT, Stenlöf K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58(6):1183–7. https://doi.org/10.1007/s00125-015-3547-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355–64. https://doi.org/10.2337/dc13-2762.

Article  CAS  PubMed  Google Scholar 

Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–26. https://doi.org/10.1177/1479164115616901.

Article  CAS  PubMed  Google Scholar